Neos Therapeutics, Inc. (NASDAQ:NEOS) Given a $12.00 Price Target at Royal Bank Of Canada

Royal Bank Of Canada set a $12.00 target price on Neos Therapeutics, Inc. (NASDAQ:NEOS) in a report published on Tuesday, MarketBeat Ratings reports. The brokerage currently has an outperform rating on the stock.

Several other equities research analysts have also recently weighed in on the company. Zacks Investment Research cut Neos Therapeutics from a hold rating to a sell rating in a research report on Thursday, May 11th. ValuEngine cut Neos Therapeutics from a sell rating to a strong sell rating in a research report on Saturday, May 27th. Finally, BMO Capital Markets reissued an outperform rating and issued a $15.00 price objective on shares of Neos Therapeutics in a research report on Tuesday, June 20th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. Neos Therapeutics presently has a consensus rating of Hold and a consensus price target of $14.00.

Shares of Neos Therapeutics (NEOS) opened at 7.20 on Tuesday. The firm’s market capitalization is $196.99 million. Neos Therapeutics has a 12-month low of $4.85 and a 12-month high of $9.60. The company has a 50-day moving average of $6.96 and a 200 day moving average of $6.97.

Neos Therapeutics (NASDAQ:NEOS) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.83) earnings per share for the quarter, meeting the consensus estimate of ($0.83). Neos Therapeutics had a negative return on equity of 889.59% and a negative net margin of 511.74%. The company had revenue of $4.91 million during the quarter. On average, analysts predict that Neos Therapeutics will post ($3.20) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://www.com-unik.info/2017/08/12/neos-therapeutics-inc-nasdaqneos-given-a-12-00-price-target-at-royal-bank-of-canada.html.

A number of hedge funds and other institutional investors have recently modified their holdings of NEOS. TIAA CREF Investment Management LLC boosted its position in shares of Neos Therapeutics by 4.9% in the second quarter. TIAA CREF Investment Management LLC now owns 46,853 shares of the company’s stock valued at $342,000 after buying an additional 2,168 shares during the period. Rhumbline Advisers boosted its position in shares of Neos Therapeutics by 13.6% in the second quarter. Rhumbline Advisers now owns 20,409 shares of the company’s stock valued at $149,000 after buying an additional 2,441 shares during the period. Falcon Point Capital LLC boosted its position in shares of Neos Therapeutics by 3.1% in the first quarter. Falcon Point Capital LLC now owns 88,279 shares of the company’s stock valued at $636,000 after buying an additional 2,691 shares during the period. Teachers Advisors LLC boosted its position in shares of Neos Therapeutics by 16.3% in the fourth quarter. Teachers Advisors LLC now owns 25,496 shares of the company’s stock valued at $149,000 after buying an additional 3,572 shares during the period. Finally, Wells Fargo & Company MN boosted its position in shares of Neos Therapeutics by 13.0% in the second quarter. Wells Fargo & Company MN now owns 54,253 shares of the company’s stock valued at $396,000 after buying an additional 6,223 shares during the period. 34.45% of the stock is owned by hedge funds and other institutional investors.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

What are top analysts saying about Neos Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Neos Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit